Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Avian Pathol ; 46(1): 52-58, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27400065

RESUMEN

Infectious bronchitis virus (IBV) is a coronavirus which affects chickens of all ages. IBV mainly causes respiratory disease but can also result in reduced weight gain, reduced egg production, increased frequency of abnormal eggs and increased rates of mortality. Vaccination is the most important way to control the disease. Nevertheless, novel strains of infectious bronchitis (IB) continue to emerge in the field. In order to respond promptly, combinations of existing IB vaccines are frequently tested to see whether they can provide cross-protection. The efficacy of a combination of vaccines based on Massachusetts, Dutch and QX-like IB strains against emerging IB Israel variant 2 and IB 793B strains was assessed by means of four challenge studies. At least 80% of the birds vaccinated with IB H120 (Mass type) combined with IB D274 (Dutch type) followed by a QX-like IB vaccine booster or vaccinated with a combination of IB H120, IB D274 and QX-like IB were protected against a challenge with IB 793B. In addition, IB 1263 (Mass type) boosted by QX-like IB showed an 85% protection following challenge with IB 793B. A combination of IB H120 and IB D274 boosted by QX-like IB vaccine conferred 70% protection whilst H120 and IB D274 combination on its own showed 61.1% protection against Israel variant 2 challenge. IB 1263 boosted by a QX-like IB vaccine showed 50% protection against IB Israel variant 2. Therefore, it can be concluded that a combination of the IB H120, IB D274 and QX-like IB confers broad protection against different non-related virulent IB strains.


Asunto(s)
Bronquitis/veterinaria , Pollos/inmunología , Infecciones por Coronavirus/veterinaria , Virus de la Bronquitis Infecciosa/inmunología , Enfermedades de las Aves de Corral/prevención & control , Vacunación/veterinaria , Vacunas Virales/inmunología , Animales , Bronquitis/prevención & control , Bronquitis/virología , Pollos/virología , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/virología , Protección Cruzada , Virus de la Bronquitis Infecciosa/patogenicidad , Israel , Massachusetts , Enfermedades de las Aves de Corral/virología , Serogrupo , Organismos Libres de Patógenos Específicos , Vacunas Atenuadas/inmunología , Virulencia
2.
Benef Microbes ; 6(5): 615-30, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25809217

RESUMEN

This study aimed to systematically evaluate safety of probiotics and synbiotics in children ageing 0-18 years. This study is the third and final part in a safety trilogy and an update is provided using the most recent available clinical data (2008-2013) by means of the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification. Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 74 clinical studies indicated that probiotic and/or synbiotic administration in children is safe with regard to the specific evaluated strains, dosages and duration. The population of children include healthy, immune compromised and obese subjects, as well as subjects with intestinal disorders, infections and inflammatory disorders. This study revealed no major safety concerns, as the adverse events (AEs) were unrelated, or not suspected to be related, to the probiotic or synbiotic product. In general the study products were well tolerated. Overall, AEs occurred more frequent in the control arm compared to children receiving probiotics and/or synbiotics. Furthermore, the results indicate inadequate reporting and classification of AEs in the majority of the studies. In addition, generalizability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes.


Asunto(s)
Probióticos/administración & dosificación , Probióticos/efectos adversos , Simbióticos/administración & dosificación , Simbióticos/efectos adversos , Adolescente , Niño , Preescolar , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Humanos , Lactante , Recién Nacido
3.
Benef Microbes ; 6(1): 3-17, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25304690

RESUMEN

This study aimed to systematically evaluate safety of probiotics and synbiotics in immune compromised adults (≥18 years). Safety was analysed using the Common Terminology Clinical Adverse Events (CTCAE version 4.0) classification, thereby providing an update on previous reports using the most recent available clinical data (2008-2013). Safety aspects are represented and related to number of participants per probiotic strain/culture, study duration, dosage, clinical condition and selected afflictions. Analysis of 57 clinical studies indicates that probiotic and/or synbiotic administration in immune compromised adults is safe with regard to the current evaluated probiotic strains, dosages and duration. Individuals were considered immune compromised if HIV-infected, critically ill, underwent surgery or had an organ- or an autoimmune disease. There were no major safety concerns in the study, as none of the serious adverse events (AE)s were related, or suspected to be related, to the probiotic or synbiotic product and the study products were well tolerated. Overall, AEs occurred less frequent in immune compromised subjects receiving probiotics and/or synbiotics compared to the control group. In addition, the results demonstrated a flaw in precise reporting and classification of AE in most studies. Furthermore, generalisability of conclusions are greatly limited by the inconsistent, imprecise and potentially incomplete reporting as well as the variation in probiotic strains, dosages, administration regimes, study populations and reported outcomes. We argue that standardised reporting on adverse events (CTCAE) in 'food' studies should be obligatory, thereby improving reliability of data and re-enforcing the safety profile of probiotics.


Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Huésped Inmunocomprometido , Probióticos/administración & dosificación , Probióticos/efectos adversos , Simbióticos/efectos adversos , Adulto , Ensayos Clínicos como Asunto , Humanos
4.
Crisis ; 34(2): 124-30, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23261910

RESUMEN

BACKGROUND: Linguistic inquiry and word count (LIWC), a computerized method for text analysis, is often used to examine suicide writings in order to characterize the quantitative linguistic features of suicidal texts. AIMS: To analyze texts compiled in Marilyn Monroe's Fragments using LIWC, in order to explore the use of different linguistic categories in her narrative over the years. METHOD: Selected texts were grouped into four periods of similar word count and processed with LIWC. Spearman's rank correlation was used to assess changes in language use across the documents over time. The Kruskal-Wallis test was applied to compare means between periods and for each of the 80 LIWC output scores. RESULTS: Significant differences (p < .05) were found in 11 categories, the most relevant being a progressive decrease in the use of negative emotion words, a reduction in the use of long words in the third period, and an increase in the proportion of personal pronouns used as Monroe approached the time of her death. CONCLUSIONS: The consistently elevated usage of first-person personal singular pronouns and the consistently diminished usage of first-person personal plural pronouns are in line with previous studies linking this pattern with a low level of social integration, which has been related to suicide according to different theories.


Asunto(s)
Personajes , Lingüística , Películas Cinematográficas/historia , Semántica , Ideación Suicida , Suicidio/historia , Escritura , Adulto , Femenino , Historia del Siglo XX , Humanos , Estados Unidos
5.
Med. mil ; 59(1): 33-34, ene.-mar. 2003. ilus
Artículo en Es | IBECS | ID: ibc-37492

RESUMEN

Presentamos el caso de una mujer de 86 años con episodios de dolor abdominal etiquetados de cuadros de suboclusión intestinal y anemia ferropénica de varios meses de evolución. Acude a Urgencias por empeoramiento del dolor cólico y deposiciones diarreicas. En la exploración abdominal se aprecia una masa epi-mesogástrica en forma de "barra gruesa". Comentamos la rareza de la invaginación intestinal en el adulto que apenas supone el 10 por ciento de las causas de obstrucción intestinal y la dificultad de conseguir un adecuado diagnóstico preoperatorio. Describimos los hallazgos clínicos y radiológicos, haciendo hincapié en la importancia de las técnicas exploratorias en la aproximación diagnóstica. Ecografia, TAC y RNM abdominal pueden ofrecer unos magníficos resultados (AU)


Asunto(s)
Anciano , Femenino , Humanos , Obstrucción Intestinal/etiología , Intususcepción/complicaciones , Válvula Ileocecal/fisiopatología , Abdomen Agudo/etiología , Intususcepción/diagnóstico , Anemia Ferropénica/complicaciones
6.
Arch Intern Med ; 161(21): 2588-95, 2001 Nov 26.
Artículo en Inglés | MEDLINE | ID: mdl-11718590

RESUMEN

BACKGROUND: Surveillance of patients with Barrett esophagus (BE) is recommended to detect dysplasia and early cancer. In 1998, practice guidelines for the surveillance of patients with BE were developed under the auspices of the American College of Gastroenterology (ACG). Our objective is to assess physicians' awareness of agreement with and adherence to these guidelines. METHODS: A national prospective cohort study of practicing gastroenterologists who completed a self-administered questionnaire containing case studies prior to the release of the guidelines and another survey 18 months later. Analysis of adherence to the guidelines was done using the McNemar chi(2) test. RESULTS: Of the 154 gastroenterologists (66%) who responded to the follow-up survey, more than half (55%) were aware of the guidelines, and members of the ACG were more likely to know of their existence than nonmembers (61% vs 38%; P =.01). Overall, about 27% of physicians reported practicing in accordance with the guidelines at baseline; adherence increased modestly to 38% in the 18-month follow-up (P =.04) and was inversely related to fee-for-service reimbursement. Awareness was not associated with an increased likelihood of adherence, but agreement with the guidelines was strongly correlated with adherence (P<.001). The most frequent reasons for disagreement were concerns about liability, cancer risk, and inadequate evidence. CONCLUSIONS: Awareness of the guidelines published by the ACG was low. Guideline awareness did not predict adherence. Improvement in guideline adherence will require steps beyond mere dissemination and promotion. Addressing disagreements about liability, disease risk, and scientific evidence as well as restructuring payment incentives may help achieve optimal practice.


Asunto(s)
Esófago de Barrett/diagnóstico , Esófago de Barrett/terapia , Guías de Práctica Clínica como Asunto , Adulto , Anciano , Actitud del Personal de Salud , Concienciación , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Adhesión a Directriz , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina , Estudios Prospectivos , Encuestas y Cuestionarios
8.
Arch Pediatr Adolesc Med ; 155(9): 1057-62, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11529809

RESUMEN

BACKGROUND: The 1997 National Heart, Lung, and Blood Institute (NHLBI) asthma guidelines include recommendations on how to improve the quality of care for asthma. OBJECTIVE: To identify barriers to physician adherence to the NHLBI guidelines. DESIGN: Cross-sectional survey. PARTICIPANTS: A national random sample of 829 primary care pediatricians. MAIN OUTCOME MEASURES: Self-reported adherence to 4 components of the NHLBI guidelines (steroid prescription, instructing peak flow meter use, screening and counseling patients with asthma for smoking, and screening and counseling parents for smoking). We also collected information on physician demographics, practice characteristics, and possible barriers to adherence. We defined adherence as following a guideline component more than 90% of the time. RESULTS: The response rate was 55% (456/829). Most of the responding pediatricians were aware of the guidelines (88%) and reported having access to a copy of the guidelines (81%). Self-reported rates of adherence were between 39% and 53% for the guideline components. After controlling for demographics and other barriers, we found that nonadherence was associated with specific barriers for each guideline component: for corticosteroid prescription, lack of agreement (odds ratio [OR], 6.8; 95% confidence interval [CI], 3.2-14.4); for peak flow meter use, lack of self-efficacy (OR, 3.4; 95% CI, 1.9-6.1) and lack of outcome expectancy (OR, 4.7; 95% CI, 2.5-8.9); and for screening and counseling of patients and parents for smoking, lack of self-efficacy (OR, 3.8; 95% CI, 1.7-6.2 and OR, 2.8; 95% CI, 1.3-5.9, respectively). CONCLUSIONS: Although pediatricians in this sample were aware of the NHLBI guidelines, a variety of barriers precluded their successful use. To improve NHLBI guideline adherence, tailored interventions that address the barriers characteristic of a given guideline component need to be implemented.


Asunto(s)
Asma/terapia , Actitud del Personal de Salud , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Corticoesteroides/administración & dosificación , Niño , Estudios Transversales , Humanos , Nebulizadores y Vaporizadores , Educación del Paciente como Asunto , Ápice del Flujo Espiratorio , Cese del Hábito de Fumar
9.
Arch Pediatr Adolesc Med ; 155(8): 915-20, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11483119

RESUMEN

BACKGROUND: Routine use of hepatitis B vaccine for low-risk newborns was suspended on July 7, 1999, because of concern about the potential risk of thimerosal, a mercury-containing vaccine preservative. Reinstatement of the birth dose was recommended when a thimerosal-free vaccine became available. OBJECTIVE: To explore changes in hepatitis B vaccination practices for newborns related to the revised recommendations for low-risk infants (in this study, the terms newborn and infant are used interchangeably). DESIGN: A telephone survey of a random sample of 1000 US hospitals. PARTICIPANTS: Nurse managers, nursery directors, and staff nurses of the newborn nurseries. MAIN OUTCOME MEASURES: Nursery vaccination practices before and after July 7, 1999, and the availability and use of thimerosal-free vaccine. RESULTS: Interviews were conducted with 773 (87%) of 886 eligible hospitals. Before July 7, 1999, 78% of the hospitals reported vaccination practices that were consistent with recommendations at that time, although only 47% vaccinated all low-risk infants at birth. After July 7, 1999, almost all hospitals discontinued vaccination of low-risk infants, in accordance with the recommendation change; however, there was a 6-fold increase in the number of hospitals that were not vaccinating all high-risk infants. After the introduction of thimerosal-free vaccine, only 39% of the hospitals reported vaccinating all low-risk infants. CONCLUSIONS: Most hospital nurseries altered their newborn hepatitis B vaccination practices consistent with changes in national recommendations. However, unintended consequences included the failure of some hospitals to continue vaccinating all high-risk infants and the delay in reintroducing vaccination for low-risk newborns after the introduction of a thimerosal-free vaccine. Assessments of the appropriateness of this country's response to the threat of thimerosal in vaccines should consider these findings.


Asunto(s)
Adhesión a Directriz/estadística & datos numéricos , Vacunas contra Hepatitis B/administración & dosificación , Hepatitis B/prevención & control , Salas Cuna en Hospital/normas , Vacunación/tendencias , Recolección de Datos , Femenino , Predicción , Humanos , Recién Nacido , Masculino , Salas Cuna en Hospital/estadística & datos numéricos , Vigilancia de la Población , Guías de Práctica Clínica como Asunto , Sensibilidad y Especificidad , Encuestas y Cuestionarios , Estados Unidos , Vacunación/normas
12.
Arch Pediatr Adolesc Med ; 154(7): 685-93, 2000 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10891020

RESUMEN

OBJECTIVE: To describe barriers to the successful use of the 1997 National Heart, Lung, and Blood Institute (NHLBI) asthma guidelines. METHODS: We conducted 3 focus groups to understand barriers to the use of 4 recommendations within the NHLBI guidelines (prescription of inhaled corticosteroids, recommendation of daily peak flowmeter use, smoking cessation screening and counseling, and allergen exposure counseling). PARTICIPANTS: Twenty-one pediatricians and 1 nurse practitioner, who each followed an average of 47 patients with asthma, participated. Six participants (27%) had a faculty or adjunct appointment at a medical school. Nineteen (90%) of the 21 pediatricians were board certified. RESULTS: We identified 171 comments about barriers to adherence. Type of recommendation and physician year of graduation from medical school were related to which barrier was prominent. For corticosteroid prescription, senior physicians mentioned lack of agreement, whereas younger physicians described lack of confidence in dosing or recognizing contraindications. For peak flow-meter use, senior physicians emphasized lack of training. Only senior physicians described the inertia of previous practice as a barrier. All groups mentioned time limitations. CONCLUSIONS: Efforts to improve adherence to asthma guidelines should consider the range of barriers that pediatricians face, such as lack of awareness, familiarity, or agreement, and external barriers owing to environmental, guideline, or patient factors. In addition, this study documents barriers not previously considered, such as lack of self-efficacy, lack of outcome expectancy, and inertia of previous practice, that prevent adherence. Because type of recommendation and physician demographics are related to which barriers are prominent, interventions to improve NHLBI guideline adherence should be tailored to these factors.


Asunto(s)
Asma/rehabilitación , Actitud del Personal de Salud , Guías de Práctica Clínica como Asunto , Adolescente , Asma/prevención & control , Niño , Curriculum , Educación Médica Continua , Femenino , Grupos Focales , Humanos , Masculino , Educación del Paciente como Asunto , Pediatría/educación , Relaciones Médico-Paciente
14.
Antimicrob Agents Chemother ; 44(5): 1132-9, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10770741

RESUMEN

Human immunodeficiency virus type 1 (HIV-1) resistance to antiretroviral drugs is the main cause of patient treatment failure. Despite the problems associated with interpretation of HIV-1 resistance testing, resistance monitoring should help in the rational design of initial or rescue antiretroviral therapies. It has previously been shown that the activity of the HIV-1 protease can be monitored by using a bacteriophage lambda-based genetic assay. This genetic screening system is based on the bacteriophage lambda regulatory circuit in which the viral repressor cI is specifically cleaved to initiate the lysogenic to lytic switch. We have adapted this simple lambda-based genetic assay for the analysis of the activities and phenotypes of different HIV-1 proteases. Lambda phages that encode HIV-1 proteases either from laboratory strains (strain HXB2) or from clinical samples are inhibited in a dose-dependent manner by the HIV-1 protease inhibitors indinavir, ritonavir, saquinavir, and nelfinavir. Distinct susceptibilities to different drugs were also detected among phages that encode HIV-1 proteases carrying different resistance mutations, further demonstrating the specificity of this assay. Differences in proteolytic processing activity can also be directly monitored with this genetic screen system since two phage populations compete in culture with each other until one phage outgrows the other. In summary, we present here a simple, safe, and rapid genetic screening system that may be used to predict the activities and phenotypes of HIV-1 proteases in the course of viral infection and antiretroviral therapy. This assay responds appropriately to well-known HIV-1 protease inhibitors and can be used to search for new protease inhibitors.


Asunto(s)
Bacteriófago lambda/efectos de los fármacos , Proteasa del VIH/metabolismo , Inhibidores de Proteasas/farmacología , Secuencia de Aminoácidos , Bacteriófago lambda/enzimología , Bacteriófago lambda/genética , Relación Dosis-Respuesta a Droga , Farmacorresistencia Microbiana , Vectores Genéticos , Proteasa del VIH/efectos de los fármacos , Proteasa del VIH/genética , Humanos , Datos de Secuencia Molecular , Mutagénesis , Homología de Secuencia de Aminoácido , Replicación Viral
15.
J Acquir Immune Defic Syndr ; 23(1): 89-94, 2000 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-10708061

RESUMEN

OBJECTIVES: To evaluate the prevalence, route of transmission and clinical significance that current co-infection with TT virus (TTV), hepatitis C virus (HCV), and hepatitis G virus (HGV) have in HIV-1-infected patients. DESIGN: Presence of TTV, HCV, and HGV was analyzed in plasma samples from 160 HIV-1-infected patients with parenteral (38 intravenous drug users [IVDUs] and 41 patients with hemophilia) or sexual (39 homosexuals and 42 heterosexuals) risk of exposure, and in 168 volunteer blood donors. Alanine aminotransferase (ALT) levels and CD4+ counts were also analyzed. METHODS: HCV and HGV RNA were detected by specific reverse transcriptase (RT) nested polymerase chain reaction (PCR) and TTV DNA by specific heminested PCR. RESULTS: TTV DNA was detected in 39% of the patients and in 14% of the volunteer blood donors. HCV and HGV infections were detected in 42% and in 14% of the patients, and in 0% and 3% of the blood donors, respectively. Prevalences of TTV and HCV infection were higher among patients with parenteral (62% and 68%) than in those with sexual (17% and 16%) risk of exposure. A higher prevalence of TTV infection (but not of HCV or HGV infection) was observed among patients with hemophilia (76%) than IVDUs (47%), and among homosexuals (26%) than among heterosexuals (10%). Abnormal ALT levels were related with the presence of HCV infection, independently of the detection of TTV DNA. TTV infection did not seem to alter the levels of CD4+ T cells. CONCLUSIONS: Prevalence of current TTV infection is high among HIV-infected patients with parenteral risk of exposure, but TTV is also transmitted through sexual routes; detection of TTV does not seem to influence the clinical or immune status of HIV-infected patients.


Asunto(s)
Infecciones por Virus ADN/epidemiología , Flaviviridae , Infecciones por VIH/complicaciones , VIH-1 , Hepatitis Viral Humana/epidemiología , Adolescente , Adulto , Alanina Transaminasa/sangre , Infecciones por Virus ADN/transmisión , Femenino , Hemofilia A , Hepatitis C/epidemiología , Hepatitis C/transmisión , Hepatitis Viral Humana/transmisión , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Sexualidad , España/epidemiología , Abuso de Sustancias por Vía Intravenosa
17.
J Med Virol ; 59(4): 480-90, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10534730

RESUMEN

The emergence of genotypic resistance in protease and reverse transcriptase (RT) gene regions was longitudinally evaluated in plasma samples from a group of 12 HIV-1-infected patients treated with different combination of antiretroviral therapies and selected on the basis of their clinical failure. Complex mutational patterns in the reverse transcriptase gene were observed. In particular, combinations of AZT (41L, 67N, 70R, 210W, and 219Q/E) and 3TC (184M) were seen in 10 patients. Two patients presented codon 151 multinucleoside analogue resistance (MNR). Additionally, seven patients harbored RT nonnucleoside analogue-related resistance substitutions (98G, 103N, and 181C). Multiple protease-selected mutations were found in each patient with an average of six substitutions per patient, with 10I/F/V, 63P, 71V, 82A/T, 84V, and 90M being the most prevalent substitutions. Overall, these results showed that for most patients virological failure was coupled with detectable genotypic resistance. Furthermore, most patients exhibited genotypic resistance to almost all available anti-HIV-1 drugs. The high viral loads found in most patients at the end of the study suggest that the replication of these multidrug resistant viruses are not severely compromised. Phylogenetic analysis of these pol sequences revealed that a specific HIV-1 genotype prone to develop multidrug resistance was not found.


Asunto(s)
Infecciones por VIH/virología , Inhibidores de la Proteasa del VIH/farmacología , VIH-1/efectos de los fármacos , VIH-1/genética , Mutación , Inhibidores de la Transcriptasa Inversa/farmacología , Adulto , Secuencia de Aminoácidos , Secuencia de Bases , Estudios de Cohortes , Secuencia de Consenso , ADN Complementario , Farmacorresistencia Microbiana/genética , Resistencia a Múltiples Medicamentos/genética , Evolución Molecular , Femenino , Infecciones por VIH/tratamiento farmacológico , Proteasa del VIH/genética , Inhibidores de la Proteasa del VIH/uso terapéutico , Transcriptasa Inversa del VIH/genética , VIH-1/clasificación , VIH-1/enzimología , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Filogenia , Reacción en Cadena de la Polimerasa , ARN Viral/sangre , Inhibidores de la Transcriptasa Inversa/uso terapéutico
18.
JAMA ; 282(15): 1458-65, 1999 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-10535437

RESUMEN

CONTEXT: Despite wide promulgation, clinical practice guidelines have had limited effect on changing physician behavior. Little is known about the process and factors involved in changing physician practices in response to guidelines. OBJECTIVE: To review barriers to physician adherence to clinical practice guidelines. DATA SOURCES: We searched the MEDLINE, Educational Resources Information Center (ERIC), and HealthSTAR databases (January 1966 to January 1998); bibliographies; textbooks on health behavior or public health; and references supplied by experts to find English-language article titles that describe barriers to guideline adherence. STUDY SELECTION: Of 5658 articles initially identified, we selected 76 published studies describing at least 1 barrier to adherence to clinical practice guidelines, practice parameters, clinical policies, or national consensus statements. One investigator screened titles to identify candidate articles, then 2 investigators independently reviewed the texts to exclude articles that did not match the criteria. Differences were resolved by consensus with a third investigator. DATA EXTRACTION: Two investigators organized barriers to adherence into a framework according to their effect on physician knowledge, attitudes, or behavior. This organization was validated by 3 additional investigators. DATA SYNTHESIS: The 76 articles included 120 different surveys investigating 293 potential barriers to physician guideline adherence, including awareness (n = 46), familiarity(n = 31), agreement (n = 33), self-efficacy (n = 19), outcome expectancy (n = 8), ability to overcome the inertia of previous practice (n = 14), and absence of external barriers to perform recommendations (n = 34). The majority of surveys (70 [58%] of 120) examined only 1 type of barrier. CONCLUSIONS: Studies on improving physician guideline adherence may not be generalizable, since barriers in one setting may not be present in another. Our review offers a differential diagnosis for why physicians do not follow practice guidelines, as well as a rational approach toward improving guideline adherence and a framework for future research.


Asunto(s)
Adhesión a Directriz , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Actitud del Personal de Salud , Recolección de Datos , Conocimientos, Actitudes y Práctica en Salud , Estados Unidos
19.
Virology ; 256(2): 180-7, 1999 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-10191182

RESUMEN

Treatment of human immunodeficiency virus type 1 (HIV-1)-infected patients with combination drug regimens results in a reduction of plasma viral load to levels below the limit of detection. To investigate the genomic fluctuations in HIV-1 populations from long-term responders to antiviral therapies we analyzed the viral sequence evolution of env and pol genes from sequential peripheral blood mononuclear cell (PBMC) DNA samples of three infected patients. Analyses of sequences covering the V3 and flanking env regions obtained from blood samples at the beginning of the therapy and at 14 or 24 months from baseline revealed that HIV-1 quasispecies continue to evolve in the three patients following combination antiretroviral therapy. Minor drug-resistant mutant subpopulations were also searched for and found in one patient. Interestingly, no minor resistant subpopulations were found in the other two patients despite the fact that they showed evidence of ongoing viral replication. Finally, the genetic analysis of the env gene shows a reduction in PBMC env viral population diversity after long-term response to the therapy in all the patients analyzed.


Asunto(s)
Evolución Molecular , Genes env , Proteína gp120 de Envoltorio del VIH/genética , Infecciones por VIH/virología , Transcriptasa Inversa del VIH/genética , VIH-1/genética , Fragmentos de Péptidos/genética , Viremia/virología , Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , Humanos , Nucleósidos/uso terapéutico , Filogenia , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...